Etodolac

證據等級: L5

預測適應症: 10 個

Etodolac: From Osteoarthritis/Rheumatic Pain to Ankylosing Spondylitis

Note on candidate selection: This Evidence Pack lists 10 TxGNN-predicted indications. The nominal #1 candidate (acromesomelic dysplasia, Hunter-Thompson type) has a TxGNN score of 99.97% but zero supporting trials/literature, and the pack’s own rationale states it has “no direct relevance to the NSAID mechanism.” Ranks 2–5, 7–9 are similarly unsupported (all L5/Hold, likely knowledge-graph proximity artifacts). Only two candidates have real evidence: Ankylosing Spondylitis (rank 6) and Inflammatory Spondylopathy (rank 10), which share nearly identical literature/trial evidence. This report focuses on Ankylosing Spondylitis as the higher-scoring, more clinically specific of the two.

One-Sentence Summary

Etodolac is a COX-2-preferential NSAID; published literature in this evidence pack documents its historical use for osteoarthritis, rheumatoid arthritis, and postoperative pain, alongside ankylosing spondylitis (AS) itself. The TxGNN model predicts continued/expanded relevance for Ankylosing Spondylitis, supported by 1 clinical trial (indirect, not etodolac-specific) and 9 publications, most dating from 1989–2011.

Quick Overview

Item	Content
Original Indication	Not formally on file (drug not marketed in this jurisdiction); per literature (PMID 1717225), historically indicated for rheumatoid arthritis, osteoarthritis, and postoperative pain
Predicted New Indication	Ankylosing Spondylitis
TxGNN Prediction Score	99.93%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Etodolac is a selective COX-2-preferential NSAID that inhibits prostaglandin synthesis, reducing inflammation and pain. This is drawn from the evidence pack’s own mechanistic rationale, since the formal original_moa field is flagged as a data gap (DG002, High severity) pending DrugBank API confirmation.

NSAIDs are already an ASAS/EULAR first-line treatment class for ankylosing spondylitis, so this is less a novel repurposing hypothesis than a documented historical use: four of the nine literature entries (PMID 1717225, 2525800, 2146130, 2150569) explicitly list AS alongside RA and OA as indications studied for etodolac in the late 1980s–1990s. The mechanistic link is therefore well established, but the supporting evidence predates modern NSAID safety classification and trial standards.

The one registered clinical trial (NCT05164198) is not an etodolac trial — it studies TNF-inhibitor dose tapering in AS — and only overlaps on patient population. It should be read as background-standard-of-care context, not direct efficacy evidence for etodolac.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05164198	Phase 4	Unknown	448	Evaluates TNF-inhibitor dose reduction in AS patients with stable disease; not an etodolac trial — relevance graded C (population overlap only)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2525800	1989	Cohort/Open trial	La Revue de médecine interne	Open trial in 4,947 RA/AS/OA patients (Lodine 200), efficacy and tolerability assessed across indications
2150569	1990	Cohort (large-scale open trial)	Rheumatology International	Two French open-label safety studies (4,947 + 51,355 patients) covering RA, AS, and OA
1717225	1991	Review	Drugs	Reappraisal of etodolac pharmacology; effective in RA, OA, AS, and postoperative pain, comparable to other NSAIDs
2146130	1990	Review	European Journal of Rheumatology and Inflammation	Randomized, double-blind, parallel-group studies comparing etodolac to naproxen/piroxicam in RA, OA, and AS
17694363	1997	Review	Inflammopharmacology	Clinical review of etodolac as multipurpose analgesic; COX-2-selective mechanism, applied in RA, AS, gout, OA
22071858	2011	Review (safety)	Cochrane Database of Systematic Reviews	Safety of NSAIDs (including etodolac class) combined with methotrexate in inflammatory arthritis incl. AS
20829199	2011	Review (methodology)	Annals of the Rheumatic Diseases	ASAS recommendations for recording NSAID intake as an outcome measure in axial spondyloarthritis trials
24449987	2013	Review	The Israel Medical Association Journal	Discussion of “indemonstrable” axial spondyloarthritis diagnosis
21140116	2010	Open prospective trial (non-etodolac)	Singapore Medical Journal	Pamidronate (not etodolac) in NSAID-refractory AS — background only, low direct relevance

US Market Information

Currently not marketed in this jurisdiction; no NDA/license records are available (total_licenses: 0).

Safety Considerations

Please refer to the package insert for safety information. Formal warnings, contraindications, and drug-interaction data are recorded as data gaps in this evidence pack — notably, TFDA label warnings/contraindications (DG001) are flagged Blocking for safety pre-screening.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Etodolac’s use in ankylosing spondylitis is mechanistically sound and historically documented across multiple cohort studies and reviews, but the evidence base is dated (mostly 1989–1997), lacks a dedicated modern RCT, and the only registered trial doesn’t test etodolac itself. This supports cautious progression, not a clean Go.

To proceed, the following is needed:

Resolve DG001 (TFDA/label warnings and contraindications) — currently blocking safety pre-screening (S1)
Resolve DG002 (confirm MOA via DrugBank API) to formalize the mechanistic rationale
Reassess GI/CV safety per current NSAID class labeling, since supporting literature predates modern safety standards
Treat Inflammatory Spondylopathy (rank 10) as an overlapping signal rather than independent confirmation, given near-identical evidence sets
Deprioritize the seven zero-evidence L5 candidates (ranks 1–5, 7–9) unless new trial/literature data emerges
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.